Sponsored Videos

Britton Jimenez, SVP of Sales and Marketing at Codexis, explains how the ECO Synthesis® Manufacturing Platform overcomes the limitations in scalability and sustainability that currently challenge the RNA therapeutics industry.

A long-term, trust-based CDMO partnership can support cell and gene therapy developers from early process development through GMP manufacturing and commercial supply.

Jonathan Haigh, Head of UK Sites, FUJIFILM Biotechnologies, explores how advanced technologies are being used to reduce risk and strengthen global supply chains for biologics.

Biopharmaceutical manufacturers can strategically choose between fed-batch and continuous manufacturing to balance scalability, flexibility, and market demand across the product lifecycle.

The biannual AustinPx Amorphous Solid Dispersions (ASD) Workshop is a place for collaboration and innovation. Hear firsthand from attendees about challenges and insights from the front lines of amorphous drug development.

Watch this interview and learn how advances in patient-centric drug delivery are transforming ten23 health's development strategies as a next-generation CDMO.

In this interview, Sandra Reid of gChem explains how PROCIPIENT®, its USP-grade DMSO, is uniquely manufactured under cGMP and ICH Q7 guidelines to ensure compliance, consistency, and quality across global pharmaceutical markets.

In this interview, Rishi Pimentel of gChem explains how PROCIPIENT®, a cGMP-compliant excipient-grade DMSO, supports advanced therapies with superior purity and sterility, mitigates risks of using industrial-grade solvents, and strengthens regulatory readiness and supply chain security.

In this interview, Dr Nigel Langley of gChem discusses the importance of excipient grade, compliance, and supply chain transparency, and introduces PROCIPIENT®, gChem’s high-purity pharmaceutical-grade DMSO.

Saleem Farooqui of Fresenius Kabi explains how the company is addressing today’s pharmaceutical manufacturing needs. Watch this video to learn how these capabilities can help bring products to market successfully.

How Techceuticals, PharmParts, and smart auction strategies are ushering in a new era of efficiency and innovation for CDMOs

Peter DeYoung, CEO at Piramal Pharma Limited, explains how Piramal is meeting the growing demand for integrated biologics manufacturing by expanding capabilities and expertise.

Dave Wood, CEO at Experic, discusses how decades of expertise with advanced technologies helps pharmaceutical and biotech partners bring products to market faster.

How gChem (formerly Gaylord Chemicals) is embracing its rebrand that aligns with green chemistry, innovation, and regulatory excellence

How BioDuro is expanding its global CRDMO footprint by improving integrated capabilities and delivering high-quality, end-to-end solutions for drug development and manufacturing

How Lonza Capsules & Health Ingredients (CHI) is redefining drug delivery with cutting-edge capsule innovation, customer-first service, and a strong commitment to sustainability

Innovative drug delivery solutions are evolving due to advances in biotechnology and the demand for biologics, focusing on user-friendly devices that improve patient compliance and support high-viscosity, large-volume treatments and various therapies.

Dean Bornilla, Pace® Life Sciences, highlights his organization's future role in supporting biopharmaceutical development and manufacturing coast-to-coast.

Colbert Packaging specializes in safe, smart, and sustainable paperboard packaging for the pharmaceutical and healthcare industries, differentiating itself through industry-focused investments and a commitment to environmental responsibility.

Dr Rupa Pike, Sr. Director & Global Head Strategic Alliances and Field Scientists for Cell Therapy, Catalent, shares insight on de-risking cell therapy programs using streamlined development and manufacturing platforms.

David McErlane, Group President of Biologics, Catalent, reacts to trends in cell and gene therapy development and manufacturing and comments on Catalent's ESG strategy to support people, the environment, and communities.

Shilpa Gadgil, PhD (VP, Head of Process and Analytical Development, Head of CDMO Development) discusses Enzene's new technologies and the New Jersey site capabilities.

Elizabeth Hickman (Chief Business Officer, AustinPx) explains the company's approach to improving bioavailability, highlighting KinetiSol technology.

Heidi Casaletto, Vice President of Global Marketing, Catalent, comments on the significance of developing biologics with a 'patient first' philosphy.

Alec McChesney (BD Director, SCORR Marketing) discusses goal setting and alignment between life sciences marketing and business development teams.

In this video, hear Albert McEvoy, Senior Director of NORAM Logistics, talk about how Marken is preparing its pharma supply chains for a new age of healthcare by optimizing drug development and delivery through cutting-edge tech, strategic partnerships, and contingency plans ― a future where patients anywhere in the world have access to essential medicines.

President and CEO of Pharmaceutics International, Inc. (Pii), John Fowler, reacts to the agility and flexibility needed to support the development and manufacture of today's complex biotherapeutics.

AST’s VP of Business Development, Josh Russell, discusses the company’s impact on the pharmaceutical industry using innovative fill/finish equipment.